SCHEMBL25233296

SCHEMBL25233296

CC(C)(C)OC(=O)N1CCN(c2nc(Br)c(Cl)s2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 1/20 0.43
POLB P06746 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CKS1B P61024 2/20 0.41
SKP1 P63208 2/20 0.41
SKP2 Q13309 2/20 0.41
MAPT P10636 2/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
KCNH2 Q12809 2/20 0.41
BACE1 P56817 1/20 0.40
SUV39H2 Q9H5I1 1/20 0.40
MAP4K4 O95819 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
MAPK8 P45983 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
USP2 O75604 1/20 0.39
GBA1 P04062 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16075322 0.79 SMN1; SMN2 (0.47) STSPOLBMEN1KMT2ACKS1B
SCHEMBL15876877 0.79 ALDH1A1 (0.44) POLBCKS1BSKP1SKP2MAPT
SCHEMBL4850285 0.77 DPP4 (0.47) MEN1KMT2ACKS1BSKP1SKP2
SCHEMBL26483104 0.77 POLB (0.44) STSPOLBMEN1KMT2ACKS1B
SCHEMBL14486374 0.77 CKS1B (0.44) CKS1BSKP1SKP2MAPTALDH1A1
SCHEMBL17578497 0.77 USP30 (0.40) MEN1KMT2ACKS1BSKP1SKP2
SCHEMBL16075308 0.76 MAPT (0.43) POLBMEN1KMT2ACKS1BSKP1
SCHEMBL1199336 0.76 GPR119 (0.49) POLBMEN1KMT2ACKS1BSKP1
SCHEMBL2070545 0.75 GBA1 (0.47) POLBCKS1BSKP1SKP2MAPT
SCHEMBL31539296 0.75 MAPT (0.49) STSPOLBMEN1KMT2ACKS1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12454529-B2 Piperazine cyclic ureas Sironax Ltd. (KY) 2025-10-28 US disclosed
US-20230203019-A1 Piperazine Cyclic Ureas SIRONAX (BEIJING) CO., LTD. (CN) 2023-06-29 US disclosed
US-20230203019-A1 Piperazine Cyclic Ureas SIRONAX (BEIJING) CO., LTD. (CN) 2023-06-29 US disclosed
US-20230203019-A1 Piperazine Cyclic Ureas SIRONAX (BEIJING) CO., LTD. (CN) 2023-06-29 US disclosed
CN-115697991-A Piperazine cyclic ureas 维泰瑞隆有限公司 2023-02-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12454529-B2 Piperazine cyclic ureas RIPK1, RIPK3, RIPK4 STS 4695/4885POLB 2439/4885MEN1 3483/4885
US-20230203019-A1 Piperazine Cyclic Ureas RIPK1, RIPK3, RIPK4 STS 4695/4885POLB 2439/4885MEN1 3483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.